SCHEMBL21990591

SCHEMBL21990591

CN(C)c1cc2c(c(CO)n1)CNC2=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.33
CSF1R P07333 1/20 0.33
KDR P35968 6/20 0.32
PIM1 P11309 2/20 0.32
CSNK1A1 P48729 2/20 0.32
CDK5 Q00535 2/20 0.32
ROCK1 Q13464 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
PLK4 O00444 1/20 0.32
CHEK1 O14757 1/20 0.32
DAPK3 O43293 1/20 0.32
ROCK2 O75116 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
CHEK2 O96017 1/20 0.32
PRKCG P05129 1/20 0.32
INSR P06213 1/20 0.32
LCK P06239 1/20 0.32
LYN P07948 1/20 0.32
RET P07949 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30227903 0.87 MAP4K1 (0.36) GRM2PIM1CSNK1A1CDK5ROCK1
SCHEMBL21990455 0.87 MAP4K1 (0.36) GRM2PIM1CSNK1A1CDK5ROCK1
SCHEMBL22012276 0.86 MAP4K1 (0.33) GRM2CSF1RPIM1CSNK1A1CDK5
SCHEMBL25099627 0.85 GRM2 (0.33) GRM2LCK
SCHEMBL25100215 0.83 JAK3 (0.37) GRM2LCKPIK3CDPIK3CBPIK3CG
SCHEMBL21990473 0.83 PARP1 (0.31) CSF1RMAP4K1
SCHEMBL25100257 0.82 DAO (0.38) CSF1RPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL21990475 0.80 CSF1R (0.33) CSF1RKDRPIM1CSNK1A1CDK5
SCHEMBL21990474 0.79 MAPK1 (0.34) CSF1RMAP4K1
SCHEMBL21990566 0.78 GRM2 (0.35) GRM2KDRPIM1CSNK1A1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
EP-3880676-B1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER (US) 2023-08-02 EP disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
US-11142525-B2 Azalactam compounds as HPK1 inhibitors PFIZER INC. (US) 2021-10-12 US disclosed
CN-113316576-A 2, 3-dihydro-1H-pyrrolo [3,4-c ] pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer 辉瑞公司 2021-08-27 CN disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors PFIZER INC. (US) 2020-06-04 US disclosed
WO-2020100027-A1 2,3-DIHYDRO-1H-PYRROLO[3,4-C]PYRIDIN-1-ONE DERIVATIVES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PFIZER INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172539-A1 Azalactam Compounds as HPK1 Inhibitors CDKN1A, HIPK1, CMPK1 GRM2 2354/4885CSF1R 410/4885KDR 969/4885
US-11142525-B2 Azalactam compounds as HPK1 inhibitors CDKN1A, HIPK1, CMPK1 GRM2 2354/4885CSF1R 410/4885KDR 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.